Grace Therapeutics, Inc.
GRCE
$4.44
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.28% | 32.62% | 9.91% | 25.56% | 65.52% |
| Total Depreciation and Amortization | 16.67% | 20.00% | 60.00% | -36.36% | -66.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -113.33% | -27.62% | -2,944.34% | -417.78% | -106.66% |
| Change in Net Operating Assets | -131.12% | -142.11% | -87.19% | 126.72% | 168.18% |
| Cash from Operations | 27.85% | -1.68% | -35.30% | -20.85% | -3.44% |
| Capital Expenditure | -- | -- | -- | -- | -175.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -99.09% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -- | -- | -100.00% | 522.72% |
| Cash from Investing | -100.00% | 171.43% | -83.15% | -100.00% | 550.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11,652.47% | 9,158.64% | 99.43% | 99.43% | -97.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -698.77% | -698.77% | -698.77% | -496.91% | -- |
| Cash from Financing | -- | -- | 86.23% | 90.68% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 201.70% | 114.42% | 127.29% | 82.09% | 2.68% |